We often talk about the assumed fact that androgen deprivation therapy (ADT) changes both the blood glucose levels as well as cholesterol levels in men who are under treatment. Researchers at the Division of General Internal Medicine & Clinical Epidemiology, University Health Network, University of Toronto, Toronto, ON. decided to formally evaluate this theory over [...]
Diagnosed with lymph-node positive prostate cancer, what are the best treatment options? Should you add surgery to hormone therapy? These are important questions which have not yet been adequately answered. To help to begin to answer this question, researchers at Department of Urologic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. and [...]
Written by our own Richard Wassersug appearing in UroToday.com BERKELEY, CA (UroToday.com) – Much has happened with the use of androgen deprivation to treat prostate cancer (PCa) patients since Charles Huggins first castrated a patient in order to alleviate the symptoms of advanced PCa. Back then, patients were generally elderly and symptomatic with either urethral [...]
One of the earliest hormone therapies (ADT) given to men to treat prostate cancer was estrogen. Estrogen, commonly known as the female hormone, was used as an ADT treatment in the early 1950s. […]
At some point in the progression of advanced prostate cancer the usual initial standard of care, hormone therapy (ADT2 or ADT3), will fail to control the progression of the cancer. Commonly, when ADT does fail we will experience an increase in our PSA scores and often see signs of disease progression on imaging tests. For [...]
Ortho Biotech & Development, a unit of Cougar Biotechnology, Inc. has unblinded their Phase 3 study of abiraterone acetate plus prednisone. In the trial the abiraterone was used for the treatment of men with metastatic advanced prostate cancer has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel. [...]
We all know that hormone therapy (ADT2) stops the production of testosterone and blocks the little testosterone that might still be produced from entering into the prostate cancer cell to “feed” the cancer. There have been a number of studies that have investigated and concluded that ADT not only stops testosterone, but also has anti-vascular [...]
One of the largest and most controversial issues for the treatment of advanced prostate cancer is the value of androgen-deprivation therapy (ADT). Most doctors use ADT as their pivotal initial treatment in the management of locally advanced and metastatic prostate cancer (PCa). But, the grand question is does it extend survival? […]
On the Advanced Prostate Cancer Listserv there was a question raised about the need to use an antiandrogen (bicalutamide/Casodex, flutamide/Eulexin, or nilutamide/Nilandron) along with degarelix, the recently approved LHRH antagonist (a drug that halts the production of testicular androgens). Doctors who are knowledgeable about the use of LHRH antagonists (Zoladex, Lupron, Eligard, Viadur and Firmagon [...]
When Degarelix (FIRMAGON) which is a gonadotrophin-releasing hormone (GnRH) receptor blocker was first approved by the Food and Drug Administration (FDA) I contacted Ferring Pharmaceuticals and spoke with their medical director. I asked if Degarelix could be used as a second line hormone therapy drug after the traditional first line GnRH agonist drugs (Lupron etc.) [...]
